1
|
Kawashima M, Matsumoto T, Nishimura T, Mashima S, Kobayashi A, Kanemitsu E, Nagata H, Tanaka T, Shimahara Y. Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 months of disease regression in a patient with breast cancer liver metastases resistant to multiple systemic chemotherapies. Int Cancer Conf J 2024; 13:153-157. [PMID: 38524659 PMCID: PMC10957837 DOI: 10.1007/s13691-024-00656-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 01/03/2024] [Indexed: 03/26/2024] Open
Abstract
Hepatic arterial infusion chemotherapy (HAIC) for liver metastases (LMs) from breast cancer is not a standard of care, but its effectiveness in patients with extensive LMs who cannot tolerate systemic therapy has been reported. Herein, we report a case of breast cancer LMs that were controlled by anthracycline-based HAIC. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38 months; letrozole, nivolumab/fulvestrant, eribulin, gemcitabine/vinorelbine, high-dose toremifene/abemaciclib, and capecitabine for 21 months in total). However, owing to its adverse effects and the continued progression of the LMs, systemic therapy was switched to HAIC (40 mg/body epirubicin on day 1, 4 mg/body mitomycin C on days 1 and 15, and 500 mg/body 5-fluorouracil on days 1, 8, and 15; 28-day courses). In response to HAIC, the LMs remarkably regressed and were controlled for 17 months without severe adverse effects. HAIC was stopped when multiple brain metastases arose, and the patient died 2 months later. This case suggests that HAIC is a reasonable option for patients with extensive LMs, even in the late stage of treatment. HAIC recipients should be carefully selected through multidisciplinary discussions as the survival benefits of HAIC over systemic treatment remain unclear. Our findings identify a potential window for the use of traditional chemotherapeutic agents such as anthracyclines. Novel strategies to improve drug delivery are warranted in the future.
Collapse
Affiliation(s)
- Masahiro Kawashima
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
- Department of Breast Surgery, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 6068507 Japan
| | - Takeshi Matsumoto
- Department of Diagnostic and Interventional Radiology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 6348522 Japan
| | - Takao Nishimura
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| | - Susumu Mashima
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| | - Atsushi Kobayashi
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| | - Eisho Kanemitsu
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| | - Hiromitsu Nagata
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| | - Toshihiro Tanaka
- Department of Diagnostic and Interventional Radiology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 6348522 Japan
| | - Yasuyuki Shimahara
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62 Asahi-cho, Yamatokoriyama, Nara 6391013 Japan
| |
Collapse
|
2
|
Kanemitsu E, Takahashi R, Nakanishi S, Sueyoshi S, Kobayashi A, Nishimura T, Nagata H. A case of rapidly progressing sarcomatous intrahepatic cholangiocarcinoma with suddenly appearing lymph node metastasis. Surg Case Rep 2024; 10:9. [PMID: 38185762 PMCID: PMC10772016 DOI: 10.1186/s40792-023-01804-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 12/26/2023] [Indexed: 01/09/2024] Open
Abstract
BACKGROUND The sarcomatous variant of carcinoma is relatively rare in intrahepatic cholangiocarcinoma (ICC). Sarcomatous ICC (SICC) is associated with a poorer prognosis compared with ICC. SICC is rarely diagnosed before surgery due to non-descriptive findings; it progresses rapidly, resulting in miserable prognosis. Here, we report a case of rapidly progressing SICC that showed a clinically significant tumor growth rate. CASE PRESENTATION A 77-year-old woman who had undergone ileocecal resection for cecal cancer 5 years previously was found to have elevated levels of the tumor marker carbohydrate antigen 19-9. Although an abdominal computed tomography (CT) scan did not detect any liver mass lesions until 3 months before this serum examination, the subsequent CT scan revealed a hypodensity 20 mm mass lesion in the right anterior section. Contrast-enhanced CT and magnetic resonance imaging revealed peripheral enhancement in the arterial-to-equilibrium phase. Fluorodeoxyglucose positron emission tomography revealed uptake in the lesion. None of the imaging modalities showed lymph node swelling or distant metastases. She underwent hepatectomy under the diagnosis of ICC or an atypical metastasis from previous cecal cancer. Although preoperative images showed no suspicious lymph node metastasis 3 weeks prior, the hilar lymph node swelled 3 cm and contained adenocarcinoma. Consequently, the patient underwent right anterior sectionectomy and lymph node dissection of the hepatoduodenal ligament. Histopathological examination revealed that the liver tumor was a poorly differentiated adenocarcinoma with sarcomatous pattern. While the patient received adjuvant gemcitabine and S-1 therapy, lymph node metastasis appeared in the mediastinum 13 months after the surgery. She received gemcitabine + cisplatin + S-1 therapy but died 20 months after surgery. CONCLUSION SICC and lymph node metastasis clinically appeared within 3 months and 3 weeks, respectively. Suspected ICC that rapidly progresses should be considered SICC and treated with early resection. SICC is often missed in clinical diagnosis and has a poor prognosis, even after curative resection. While an alternative strategy involving preoperative biopsy and neoadjuvant therapy may be beneficial, it should be approached with discretion due to the potential risks of tumor progression and peritoneal dissemination.
Collapse
Affiliation(s)
- Eisho Kanemitsu
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62, Asahi-Cho, Yamatokoriyama, Nara, 639-1013, Japan.
| | - Rei Takahashi
- Graduate School of Pharmaceutical Science, Doshisha Women's College of Liberal Arts, 97-1, Kodo, Kyotanabe, Kyoto, 610-0395, Japan
| | - Setsuko Nakanishi
- Department of Radiology, JCHO Yamatokoriyama Hospital, 1-62, Asahi-Cho, Yamatokoriyama, Nara, 639-1013, Japan
| | - Satoru Sueyoshi
- Department of Radiology, Saiseikai Chuwa Hospital, 323, Abe, Sakurai, Nara, 633-0054, Japan
| | - Atsushi Kobayashi
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62, Asahi-Cho, Yamatokoriyama, Nara, 639-1013, Japan
| | - Takao Nishimura
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62, Asahi-Cho, Yamatokoriyama, Nara, 639-1013, Japan
| | - Hiromitsu Nagata
- Department of Surgery, JCHO Yamatokoriyama Hospital, 1-62, Asahi-Cho, Yamatokoriyama, Nara, 639-1013, Japan
| |
Collapse
|
3
|
Nishimura T. What we should focus on and reach out to. ESMO Open 2023; 8:102061. [PMID: 37922689 PMCID: PMC10651436 DOI: 10.1016/j.esmoop.2023.102061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 09/29/2023] [Indexed: 11/07/2023] Open
Affiliation(s)
- T Nishimura
- Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan; Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
| |
Collapse
|
4
|
Tabuchi Y, Yasui K, Ogawa H, Onoe T, Maki S, Asakura H, Nishimura T, Takahashi T, Murayama S, Harada H. The Incidence of Severe Radiation-Induced Lymphopenia during Chemoradiotherapy for Stage Ⅲ Non-Small Cell Lung Cancer: A Comparative Study of Proton Versus Photon-Based Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e62. [PMID: 37785857 DOI: 10.1016/j.ijrobp.2023.06.783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To investigate the incidence of severe radiation-induced lymphopenia (SRL) and the survival in patients with stage Ⅲ non-small cell lung cancer treated with concurrent chemoradiotherapy with passive scattering proton beam (PSPT) or photon-based radiotherapy (XRT) including 3D-CRT and IMRT. MATERIALS/METHODS We conducted a retrospective cohort study including 355 patients who received definitive concurrent chemoradiotherapy with PSPT (n = 38) or XRT (n = 317) at our institution between January 2010 and December 2020. SRL during concurrent chemoradiotherapy was defined as absolute lymphocyte counts (ALCs) of <500 cells/mm3. Propensity score matching (PSM) analysis was performed to adjust for the patient characteristics between the PSPT and XRT groups. Propensity scores were calculated using age, sex, PS (0-1 vs. 2), primary tumor location (upper/middle vs. lower lobe), pathology (Adeno vs. Others), PTV volume, ALCs at pretreatment, year of treatment (before vs. after July 2018, when durvalumab approved in Japan), and platinum-based chemotherapy regimen (CDDP based vs. CBDCA based). After PSM, the incidence of SRL and the overall survival (OS) were analyzed. RESULTS The GTV and PTV volumes were significantly lower in the PSPT group than in the XRT group (median, 57 vs. 103 mm3; p < 0.05, 322 vs. 399 mm3; p < 0.05, respectively). ALCs at pretreatment were significantly lower in the PSPT group than in the XRT group (median, 1531 vs. 1718 cells/mm3; p < 0.05). SRL was observed in 275 patients (87%) in the XRT group and 27 patients (71%) in the PSPT group (p < 0.05). After PSM, PSPT significantly reduced the incidence of SRL compared to XRT (68.6 % vs. 88.6 %, p < 0.05), and the patients without SRL may have better 3-year OS than those with SRL (71.1 % vs. 55.3 %; p = 0.062). CONCLUSION Compared with XRT, PSPT significantly reduced the incidence of SRL, and the patients without SRL had a good prognosis.
Collapse
Affiliation(s)
- Y Tabuchi
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - K Yasui
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - H Ogawa
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - T Onoe
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Maki
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - H Asakura
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - T Nishimura
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Murayama
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - H Harada
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| |
Collapse
|
5
|
Yamaguchi H, Fukumitsu N, Numajiri H, Ogino H, Okimoto T, Ogino T, Nishimura T. The Japanese Nationwide Cohort Data of Proton Beam Therapy for Liver Oligometastasis in Breast Cancer Patients. Int J Radiat Oncol Biol Phys 2023; 117:e352. [PMID: 37785219 DOI: 10.1016/j.ijrobp.2023.06.2428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) A nationwide multicenter cohort study on particle therapy was launched by the Japanese Society for Radiation Oncology (JASTRO) in Japan. We analyzed the outcome of proton beam therapy (PBT) for liver oligometastasis in breast cancers. MATERIALS/METHODS Cases in which PBT was performed at all Japanese proton therapy facilities between May 2016 and February 2019 were enrolled. The patients were selected based on the following criteria: the primary cancer was controlled, liver recurrence without extrahepatic tumors, and no more than three liver lesions. The treatment indication and strategy were discussed at cancer boards in each institution. The dose and fraction of PBT were determined by referring to the unified treatment policy established by JASTRO. We used the following protocol: 64 gray (Gy) (relative biological effectiveness [RBE])/8 fraction (fr) for the hepatic periphery area away from the GI tract, and 72.6 GyE/22 fr for the adjacent hilar region type. Regarding safety, the HCC irradiation protocols of 66 GyE/10 fr, 72.6-76 GyE/20-22 fr, and 74-76 GyE/37-38 fr could be used. The local control (LC), overall survival (OS), and progression free survival (PFS) rates were calculated using the Kaplan-Meier method. Factors possibly related to OS, such as tumor size, number of liver tumors, intervention of chemotherapy, and/or hormone therapy, were investigated. The cut-off values were estimated using the receiver operating characteristic curve and area under the curve. Univariate analysis was performed using the log-rank test. RESULTS Fourteen females, with a median age of 57 (range, 44-73) years and twenty-two lesions were included. Nine patients had one lesion, two patients had two lesions, and three patients had three lesions. PBT was selected because nine patients had underlying disease and five patients had general conditions (age, etc.). The median lesion size, fraction size, and biological effective dose using the linear-quadratic model with α/β = 10 Gy ((BED)10) were 44 (20-130) mm, 6.6 (2-8) (relative biological effectiveness [RBE])/fraction (fr), and 109.6 (52.7-115.2) Gy, respectively. The median follow-up period of breast cancers was 22.8 (4-54) months. The 1-, 2-, and 3-year LC rates of liver metastasis from breast cancers were 100% for all. The 1-, 2-, and 3-year OS rates were 85.7%, 62.5%, and 62.5%, respectively. The 1-, 2-, and 3-year PFS rates were 50.0%, 33.3%, and 16.7%, respectively, and median PFS time was 16 months. Tumor size, the number of liver tumors, and the intervention of chemotherapy and/or hormone therapy at any time were not significantly related to the OS. Only one patient did not complete PBT due to current disease progression. The other patients completed PBT without interruption. One patient had grade 3 radiation-induced dermatitis. CONCLUSION Based on the low incidence of adverse events and the high LC rate, PBT appears to be a feasible option for liver oligometastasis in breast cancer patients.
Collapse
Affiliation(s)
- H Yamaguchi
- Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan
| | | | - H Numajiri
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - H Ogino
- Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan
| | - T Okimoto
- Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan
| | - T Ogino
- Medipolis Proton Therapy and Research Center, Ibusuki, Japan
| | - T Nishimura
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| |
Collapse
|
6
|
Saito T, Shikama N, Takahashi T, Nakamura N, Aoyama H, Nakajima K, Koizumi M, Sekii S, Ebara T, Kiyohara H, Higuchi K, Yorozu A, Nishimura T, Ejima Y, Harada H, Araki N, Miwa M, Yamada K, Kawamoto T, Onishi H, Imano N. Quality of Palliative Radiation Therapy Assessed Using Quality Indicators: A Multicenter Survey. Int J Radiat Oncol Biol Phys 2023; 117:e111. [PMID: 37784649 DOI: 10.1016/j.ijrobp.2023.06.890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Clinical practice is not always performed in accordance with guideline recommendations. Quality indicators (QIs) are valuable tools for evaluating the quality of healthcare systems. We sought to identify potential gaps between clinical practice and evidence using QIs previously developed using a modified Delphi method. MATERIALS/METHODS We used seven QIs (Table 1) to assess the quality of radiation therapy for bone (BoM) and brain metastases (BrM) at 29 centers; 13 (45%) were academic (12 university hospitals and 1 cancer center) and 16 (55%) were nonacademic hospitals. Compliance rate was calculated as the percentage of patients for whom recommended medical care was conducted. Random effects models were used to estimate pooled compliance rates. Mixed effects models with a Q test were used to compare compliance rates between academic and nonacademic centers. RESULTS The estimates of the compliance rates with 95% confidence intervals are presented in Table 1. For BoM-1, the compliance rate was higher in academic hospitals (100% [100-100%]) than in non-academic hospitals (96% [89-100%]) (P = 0.021). For BrM-3, the compliance rate was lower in academic hospitals (92% [81-99%]) than in nonacademic hospitals (100% [98-100%]) (P = 0.016). CONCLUSION A quality assessment based on these seven QIs is feasible. Overall, compliance rates were high; however, for BoM-3, the practice remains to be improved in some centers. Based on BoM-4 compliance rates, steroids are infrequently used concurrently with radiation therapy for malignant spinal cord compression. Extended fractionation for BoM was less frequently performed in academic than in nonacademic centers. The initiation of radiation therapy for brain metastases was more frequently delayed in academic than in nonacademic centers.
Collapse
Affiliation(s)
- T Saito
- Department of Radiation Oncology, Arao Municipal Hospital, Kumamoto, Japan
| | - N Shikama
- Division of Radiation Oncology, Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - T Takahashi
- Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | - N Nakamura
- Department of Radiation Oncology, St. Marianna University School of Medicine, Kanagawa, Japan
| | - H Aoyama
- Department of Radiation Oncology, Faculty and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - K Nakajima
- Asahikawa Medical College, Asahikawa, Japan
| | - M Koizumi
- Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - S Sekii
- Kita-Harima Medical Center, Hyogo, Japan
| | - T Ebara
- Department of Radiation Oncology, Kyorin University, Mitaka, Tokyo, Japan
| | - H Kiyohara
- Department of Radiation Oncology, Japanese Red Cross Maebashi Hospital, Gunma, Japan
| | - K Higuchi
- Department of Radiation Oncology, Isesaki Municipal Hospital, Gunma, Japan
| | - A Yorozu
- Department of Radiation Oncology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - T Nishimura
- Department of Radiology, Fukuchiyama City Hospital, Kyoto, Japan
| | - Y Ejima
- Department of Radiology, Dokkyo Medical University, Koshigaya, Japan
| | - H Harada
- Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
| | - N Araki
- Department of Radiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - M Miwa
- Department of Radiation Oncology, Sendai Kousei Hospital, Sendai, Japan
| | - K Yamada
- Department of Radiation Oncology, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - T Kawamoto
- Division of Radiation Oncology, Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - H Onishi
- University of Yamanashi, Chuo, Japan
| | - N Imano
- Department of Radiation Oncology, Graduate School of Biomedical Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
7
|
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, D'Alessandro-Gabazza C, Gabazza E, Kobayashi T. 1535P Efficacy and safety of amrubicin after treatment with immune checkpoint inhibitor combined with chemotherapy in extensive-stage small cell carcinoma: MiSSION1. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Son BK, Imoto T, Inoue T, Nishimura T, Tanaka T, Iijima K. Social Detachment Influenced Muscle Mass and Strength during the COVID-19 Pandemic in Japanese Community-Dwelling Older Women. J Frailty Aging 2022; 11:231-235. [PMID: 35441202 PMCID: PMC8795718 DOI: 10.14283/jfa.2022.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Social detachment due to coronavirus disease (COVID-19) has caused a decline in physical activity, leading to sarcopenia and frailty in older adults. This study aimed to compare muscle mass, strength, and function values in older women before and after the first wave of the COVID-19 pandemic (April-May 2020). Furthermore, changes in muscle measures across women who experienced different levels of impact on their social participation due to the COVID-19 pandemic were examined. Muscle mass (total, trunk, and appendicular muscle), grip strength, oral motor skills, social interactions (social network and participation), and social support were assessed in 46 Japanese community-dwelling older women (mean, 77.5 y; range 66-93 y) before and after the first wave of the COVID-19 pandemic. Trunk muscle mass significantly decreased after the first wave of the pandemic. When comparing changed values between the enhanced/maintained and reduced group during the pandemic, significant group difference was observed in trunk muscular mass, grip strength, and oral motor skills. Intriguingly, those who enhanced social participation had a positive change of grip strength values, showing that social participation might influence muscle function during the COVID-19 pandemic.
Collapse
Affiliation(s)
- B K Son
- Son BK, PhD., Institute of Gerontology, Department of Geriatric Medicine, Graduate School of Medicine, Institute for Future Initiatives, The University of Tokyo, Tokyo, Japan, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81 3 5800 6534, Fax: 81 3 5800 8837, E-mail:
| | | | | | | | | | | |
Collapse
|
9
|
Doi S, Yamada T, Kito Y, Obara S, Fujii Y, Nishimura T, Kato T, Nakayama H, Tsutsumi M, Okamura R. Adult-Onset Focal Nesidioblastosis With Nodular Formation Mimicking Insulinoma. J Endocr Soc 2022; 6:bvab185. [PMID: 35024540 PMCID: PMC8743044 DOI: 10.1210/jendso/bvab185] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Indexed: 11/21/2022] Open
Abstract
Nesidioblastosis is defined as the neoformation of the islets of Langerhans from the pancreatic ductal epithelium and is recognized as the most common cause of hyperinsulinemic hypoglycemia in infants. We herein report an extremely rare case of adult-onset focal nesidioblastosis with the unusual feature of hyperplastic nodular formation. A 55-year-old woman was admitted to our hospital for a tumor detected in the body of the pancreas by magnetic resonance imaging screening. Laboratory examinations showed a high insulin level in the blood. Contrast-enhanced computed tomography and the selective arterial calcium injection test suggested the presence of multiple insulinomas in the body and tail of the pancreas, and, thus, the patient underwent distal pancreatectomy. A histopathological examination of the tumor in the body of the pancreas showed the nodular hyperplasia of islet-like cell clusters. In addition, many small intralobular ductules and islet cells appeared to be budding from the proliferating ductal epithelium, forming “ductuloinsular complexes”. No other abnormal lesion was detected in the remainder of the pancreas. The histopathological diagnosis was focal nesidioblastosis. The patient has remained free of the recurrence of hypoglycemic episodes for more than 31 months. The present case of rare adult-onset focal nesidioblastosis with hyperplastic nodular formation was preoperatively identified as an apparent pancreatic tumor mimicking insulinoma. Nesidioblastosis and insulinoma need to be considered in cases of hyperinsulinemic hypoglycemia, even in adult patients.
Collapse
Affiliation(s)
- Shunsuke Doi
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Takatsugu Yamada
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Yoshinori Kito
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Shinsaku Obara
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Yusuke Fujii
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Takao Nishimura
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Tatsushi Kato
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Hiroyuki Nakayama
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| | - Masahiro Tsutsumi
- Department of Pathology, Saiseikai Chuwa Hospital, Nara 633-0054, Japan
| | - Ryuji Okamura
- Department of Surgery, Yamatotakada Municipal Hospital, Nara 635-8501, Japan
| |
Collapse
|
10
|
Kano T, Nagata Y, Sawada R, Ishimoto U, Nishimura T, Noguchi M, Ohkuma M, Kosuge M, Amano K, Eto K, Saruta M. Tolerability and feasibility of oxaliplatin-containing adjuvant chemotherapy for elderly patients with colorectal cancer. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00343-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Senoo K, Yukawa A, Okura T, Iwakoshi H, Nishimura T, Matoba S. Geriatric depression and quality of life in atrial fibrillation: the geriatric population analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background and purpose
Arrhythmias such as atrial fibrillation (AF) is often associated with depression, with vague anxiety about symptom and the risk of serious complication such as stroke or heart failure. In the geriatric population, geriatric depression often occurs with an increase of physical illness and has substantial costly and quality of life implications for functionality and life satisfaction. However, few studies have investigated relationship between geriatric depression and Quality of Life (QoL), and arrhythmia symptoms (palpitation, dyspnea and chest discomfort).
Method
Between November 2019 and October 2020, elderly people (≥65 years) who participated in the AF awareness symposium were enrolled in this study. They were divided into 4 groups according to the presence or absence of chest symptom and AF, and were examined geriatric depression by Geriatric depression scale (GDS)-15 and Quality of Life (QoL) by the 12-item Short- Form Health Survey (SF-12) including physical and mental health status.
Results
Of the 1511 subjects, 1364 were analyzed after excluding 147 with missing values. Among them, 911 were in the non-AF group without symptom (Group A), 43 in the AF group without symptom (group B), 323 in the non-AF group with symptom (group C), and 87 in the AF group with symptom (group D).
Geriatric depression rates (defined as GDS-15 ≥10) were 2.7% in non-symptomatic group (2.7% in A [n=25] and 2.3% in B [n=1]) and 7.8% in symptomatic group (7.4% in C [n=24] and 9.2% in D [n=8]). (P<0.05) In multivariate regression analysis, an increased risk of geriatric depression was observed in groups C and D (group C: odds ratio [OR]=2.54, CI: 1.40, 4.61, P<0.01 and group D: OR=3.13 CI: 1.16, 7.57, P=0.02).
The mean values of physical and mental health status in SF-12 were 48.5 (±7.9) and 56.7 (±6.8) in A, 44.6 (±10.7) and 57.3 (±7.3) in B, 45.0 (±9.9) and 53.8 (±7.7) in C, and 43.4 (±10.8) and 54.8 (±8.6) in D, respectively. Physical health status in SF-12 was associated with group C (C vs A: estimate −2.95 [CI: −4.03, −1.87], p<0.01) and D (D vs A: estimate −2.93 [CI: −4.88, −0.97], p<0.01), other than heart failure, older age and female. Mental health status in SF-12 was associated with group C (C vs A: estimated −2.34 [CI: −3.72, −1.42], p<0.01), heart failure, hypertension, older age, female and group D (D vs A: estimate −1.63 [CI: −3.31, 0.05], p=0.06), but not statistically significant. Individuals with arrhythmia symptom (group C and D) had lower physical and mental health status than those without (group A and B) (P<0.05).
Conclusion
Older adults with arrhythmia symptoms were more likely to have geriatric depression and low QoL, especially those with symptomatic AF, with a geriatric depressive complication rate of 9.2%. Further studies are needed to investigate whether improving physical health status can improve QoL and geriatric depression.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- K Senoo
- Kyoto Prefectural University of Medicine, Department of Cardiac Arrhythmia Research and Innovation, Kyoto, Japan
| | - A Yukawa
- Kyoto Prefectural University of Medicine, Department of Cardiac Arrhythmia Research and Innovation, Kyoto, Japan
| | - T Okura
- Kyoto Prefectural University of Medicine, Department of Cardiovascular medicine, Kyoto, Japan
| | - H Iwakoshi
- Kyoto Prefectural University of Medicine, Department of Cardiovascular medicine, Kyoto, Japan
| | - T Nishimura
- Kyoto Prefectural University of Medicine, Department of Cardiovascular medicine, Kyoto, Japan
| | - S Matoba
- Kyoto Prefectural University of Medicine, Department of Cardiovascular medicine, Kyoto, Japan
| |
Collapse
|
12
|
Nishimura T, Senoo K, Hibiki I, Okura T, Miki T, Shiraishi H, Nakamura T, Matoba S. Combination of CHARGE AF score and index of 24-hour electrocardiogram to predict incident atrial fibrillation and cardiovascular events. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is associated with increased risks of stroke and heart failure. AF risk prediction can facilitate the efficient deployment of diagnosis or interventions to prevent AF.
Purpose
We sought to assess the combination prediction value of Holter electrocardiogram (Holter ECG) and the CHARGE-AF score (Cohorts for Aging and Research in Genomic Epidemiology-AF) for the new-onset of AF in a single center study. We also investigated the association between clinical findings and the new-onset of cerebral cardiovascular events.
Methods
From January 2008 and May 2014, 1246 patients with aged≥20 undergoing Holter ECG for palpitations, dizziness, or syncope were recruited. Among them, 350 patients were enrolled in this study after exclusion of 1) AF history at the time of inspection or before, 2) post cardiac device implantation, 3) follow-up duration <1 year, and 4) no 12-lead ECG records within 6 months around Holter ECG.
Results
During the 5.9-year follow-up, 40 patients (11.4%) developed AF incidence. Multivariate cox regression analysis revealed that CHARGE-AF score (hazard ratio [HR]: 1.59, 95% confidence interval (95% CI): 1.13–2.26, P<0.01), BMI (HR: 0.91, 95% CI: 0.83–0.99, P=0.03), frequent supraventricular extrasystoles (SVEs) ≥1000 beats/day (HR: 4.87, 95% CI: 2.59–9.13, P<0.001) and first-degree AV block (HR: 3.52, 95% CI: 1.63–7.61, P<0.01) were significant independent predictors for newly AF. The area under the ROC curve (AUC) of the combination of the CHARGE-AF score and frequent SVEs (≥1000) was greater than the CHARGE-AF score alone (0.73, 95% CI: 0.64–0.82 vs 0.66, 95% CI: 0.56–0.75, respectively). On the ROC curve, the CHARGE-AF score of 12.9 was optimum cut-off value for newly AF. Patients with both the CHARGE-AF score≥12.9 and SVEs≥1000 developed AF at 129.0/1000 person-years, compared with those with the CHARGE-AF score<12.9 and SVEs≥1000 (48.9), the CHARGE-AF score≥12.9 and SVEs<1000 (40.0) and the CHARGE-AF score<12.9 and SVEs<1000 (7.4), respectively. In multivariate cox regression analysis, age, past history of congestive heart failure and myocardial infarction, and antihypertensive medication were significant predictors of cerebral cardiovascular events (n=43), all of which signifying the components of the CHARGE-AF score. The AUC of the combination of the CHARGE-AF score and frequent SVEs (≥1000) was not different from the CHARGE-AF score alone (0.73, 95% CI: 0.64–0.81 vs 0.73, 95% CI: 0.64–0.82, respectively).
Conclusion
CHARGE-AF score has higher predictive power of both the new incident AF and cerebral cardiovascular events. The combination of CHARGE-AF score and SVEs≥1000 beats/day in Holter ECG can demonstrate the additional effect of prediction ability for the new incident AF, but not for cerebral cardiovascular events.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- T Nishimura
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - K Senoo
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - I Hibiki
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - T Okura
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - T Miki
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - H Shiraishi
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - T Nakamura
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | - S Matoba
- Kyoto Prefectural University of Medicine, Cardiology, Kyoto, Japan
| | | |
Collapse
|
13
|
Kawaguchi K, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga R, Tamura N, Aruga T, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Toi M. 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Asao T, Yasui K, Ota N, Shioi M, Hayashi K, Maki S, Ito Y, Onoe T, Ogawa H, Asakura H, Murayama S, Nishimura T, Takahashi T, Ohde Y, Harada H. PO-1202 Proton Beam Therapy for Stage I and Lymph Node-Negative Stage IIA Non-Small Cell Lung Cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07653-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Cruz-Atienza VM, Tago J, Villafuerte C, Wei M, Garza-Girón R, Dominguez LA, Kostoglodov V, Nishimura T, Franco SI, Real J, Santoyo MA, Ito Y, Kazachkina E. Short-term interaction between silent and devastating earthquakes in Mexico. Nat Commun 2021; 12:2171. [PMID: 33846327 PMCID: PMC8042113 DOI: 10.1038/s41467-021-22326-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Accepted: 03/11/2021] [Indexed: 02/01/2023] Open
Abstract
Either the triggering of large earthquakes on a fault hosting aseismic slip or the triggering of slow slip events (SSE) by passing seismic waves involve seismological questions with important hazard implications. Just a few observations plausibly suggest that such interactions actually happen in nature. In this study we show that three recent devastating earthquakes in Mexico are likely related to SSEs, describing a cascade of events interacting with each other on a regional scale via quasi-static and/or dynamic perturbations across the states of Guerrero and Oaxaca. Such interaction seems to be conditioned by the transient memory of Earth materials subject to the "traumatic" stress produced by seismic waves of the great 2017 (Mw8.2) Tehuantepec earthquake, which strongly disturbed the SSE cycles over a 650 km long segment of the subduction plate interface. Our results imply that seismic hazard in large populated areas is a short-term evolving function of seismotectonic processes that are often observable.
Collapse
Affiliation(s)
- V. M. Cruz-Atienza
- grid.9486.30000 0001 2159 0001Instituto de Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - J. Tago
- grid.9486.30000 0001 2159 0001Facultad de Ingeniería, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - C. Villafuerte
- grid.9486.30000 0001 2159 0001Posgrado en Ciencias de la Tierra, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - M. Wei
- grid.20431.340000 0004 0416 2242Graduate School of Oceanography, University of Rhode Island, Narragansett, USA
| | - R. Garza-Girón
- grid.205975.c0000 0001 0740 6917Department of Earth and Planetary Sciences, University of California, Santa Cruz, USA
| | - L. A. Dominguez
- grid.9486.30000 0001 2159 0001Escuela Nacional de Estudios Superiores, Universidad Nacional Autónoma de México, Morelia, Mexico
| | - V. Kostoglodov
- grid.9486.30000 0001 2159 0001Instituto de Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - T. Nishimura
- grid.258799.80000 0004 0372 2033Disaster Prevention Research Institute, Kyoto University, Kyoto, Japan
| | - S. I. Franco
- grid.9486.30000 0001 2159 0001Instituto de Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - J. Real
- grid.9486.30000 0001 2159 0001Instituto de Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - M. A. Santoyo
- grid.9486.30000 0001 2159 0001Instituto de Geofísica, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Y. Ito
- grid.258799.80000 0004 0372 2033Disaster Prevention Research Institute, Kyoto University, Kyoto, Japan
| | - E. Kazachkina
- grid.9486.30000 0001 2159 0001Posgrado en Ciencias de la Tierra, Universidad Nacional Autónoma de México, Mexico City, Mexico
| |
Collapse
|
16
|
Asase M, Watanabe T, Takegami M, Nishimura K, Kinugawa K, Nishimura T, Toda K, Saiki Y, Niinami H, Nunoda S, Matsumiya G, Nishimura M, Arai H, Yanase M, Nakatani T, Sakata Y, Ono M, Nin K, Fukushima N. Impact of Type of Left Ventricular Assist Device (LVAD) on Health-Related Quality of Life during Prolonged LVAD Support. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
17
|
Sato M, Inai K, Ogiso M, Kudo Y, Nishimura T, Mori H, Harada G, Asagai S, Shimada E, Ishido M, Takeuchi D, Toyohara K, Shinohara T, Sugiyama H. Platelet volume indices correlate to severity of heart failure and have prognostic value for both cardiac and thrombotic events in patients with congenital heart disease. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Patients with heart failure are reported to have activated platelets leading to thrombotic events. Consequently, immature giant platelets are produced, and platelet distribution width (PDW) and mean platelet volume (MPV) increase. These platelet indices are easily, reasonably, and safely available by routine blood test and recently have been proposed as potential markers of cardiac events. However, little is known about the usefulness of platelet indices in patients with congenital heart disease (CHD).
Purpose
To test whether the hypothesis that PDW and MPV correlate to the severity of heart failure and have prognostic value in both future heart failure-related admission and thrombosis formation in patients with CHD.
Methods
We performed a retrospective, single-centre study that included 400 patients with CHD (median age, 34 years [range: 12–76]; 49% males; 35% single ventricular morphology), who were admitted in our institute between April 2014 and June 2017. We reviewed patients' medical records to assess their clinical information including medical history, blood sample data, and echocardiologic parameters. At first, we assessed the correlation between platelet indices and patients' clinical parameters. Next, we compared platelet indices before and after treatment for heart failure. Finally, using logistic regression and Kaplan-Meier analyses, we assessed prognostic factors of future heart failure-related admission and thrombosis formation.
Results
In multivariate analysis, a significant correlation was found between PDW and logBNP (brain natriuretic peptide) (p<0.001), haemoglobin (p=0.01), D-dimer (p=0.019), Fontan operation (p<0.001) and male sex (p<0.001); as well as between MPV and logBNP (p<0.001), D-dimer (p<0.001) and Fontan operation (p=0.002). Throughout treatment of heart failure, significant reduction was found both in PDW (average value before treatment = 14.2, after treatment = 13.2, p=0.002) and MPV (before = 11.2, after = 10.8, p=0.004). In multivariate logistic regression analysis, predictors of future heart failure-related admissions were PDW (hazard ratio [HR]: 1.365; 95% confidence interval [CI]: 1.005–1.768), MPV (HR: 1.472; 95% CI: 1.055–2.052), age (HR: 1.063; 95% CI: 1.010–1.119), and SpO2 under 85% (HR: 5.089; 95% CI: 1.350–19.18). Using the same analysis, predictors of thrombotic formation were PDW (HR: 1.998; 95% CI: 1.461–2.630), MPV (HR: 1.792; 95% CI: 1.155–2.781), logBNP (HR: 1.196, 95% CI: 1.085–1.320), D-dimer (HR: 1.024; 95% CI: 1.007–1.042) and male sex (HR: 3.071; 95% CI: 1.079–8.737). In addition, during median follow-up of 28 months, the Kaplan-Meier analysis showed an improvement in both heart failure and thrombosis-free survival in the low PDW, as well as the low MPV group.
Conclusion
Platelet volume indices correlate to severity of heart failure and have prognostic value for both cardiac and thrombotic events in patients with congenital heart disease.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Sato
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - K Inai
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - M Ogiso
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - Y Kudo
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - T Nishimura
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - H Mori
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - G Harada
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - S Asagai
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - E Shimada
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - M Ishido
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - D Takeuchi
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - K Toyohara
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - T Shinohara
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| | - H Sugiyama
- Tokyo Women's Medical University, The department of pediatric cardiology, Tokyo, Japan
| |
Collapse
|
18
|
Ota N, Hirata M, Yasui K, Yamamoto A, Maki S, Ito Y, Onoe T, Ogawa H, Asakura H, Murayama S, Deguchi S, Mitsuya K, Harada H, Hayashi N, Nishimura T. LINAC-Based Stereotactic Irradiation For Patients With Up To Ten Brain Metastases. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Wilkes MC, Siva K, Chen J, Varetti G, Youn MY, Chae H, Ek F, Olsson R, Lundbäck T, Dever DP, Nishimura T, Narla A, Glader B, Nakauchi H, Porteus MH, Repellin CE, Gazda HT, Lin S, Serrano M, Flygare J, Sakamoto KM. Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase. Nat Commun 2020; 11:3344. [PMID: 32620751 PMCID: PMC7334220 DOI: 10.1038/s41467-020-17100-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 05/26/2020] [Indexed: 01/30/2023] Open
Abstract
Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency. DBA is characterized by anemia, congenital anomalies, and cancer predisposition. Treatment for DBA is associated with significant morbidity. Here, we report the identification of Nemo-like kinase (NLK) as a potential target for DBA therapy. To identify new DBA targets, we screen for small molecules that increase erythroid expansion in mouse models of DBA. This screen identified a compound that inhibits NLK. Chemical and genetic inhibition of NLK increases erythroid expansion in mouse and human progenitors, including bone marrow cells from DBA patients. In DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid hematopoietic lineages or healthy erythroblasts. We propose that NLK mediates aberrant erythropoiesis in DBA and is a potential target for therapy. Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome that is associated with anemia. Here, the authors examine the role of Nemo-like kinase (NLK) in erythroid cells in the pathogenesis of DBA and as a potential target for therapy.
Collapse
Affiliation(s)
- M C Wilkes
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - K Siva
- Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, 22184, Sweden
| | - J Chen
- Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, 22184, Sweden
| | - G Varetti
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, 08028, Spain.,Barcelona Institute of Science and Technology (BIST), Barcelona, 08028, Spain.,Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, 08028, Spain
| | - M Y Youn
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - H Chae
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - F Ek
- Chemical Biology and Therapeutics Group, Department of Medical Science, Lund University, Lund, 22184, Sweden
| | - R Olsson
- Chemical Biology and Therapeutics Group, Department of Medical Science, Lund University, Lund, 22184, Sweden
| | - T Lundbäck
- Chemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Department for Medical Biochemistry and Biophysics, Karolinska Institutet, 17177, Stockholm, Sweden
| | - D P Dever
- Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - T Nishimura
- Department of Genetics, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - A Narla
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - B Glader
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - H Nakauchi
- Department of Genetics, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.,Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan
| | - M H Porteus
- Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA
| | - C E Repellin
- Biosciences Division, SRI International, Menlo Park, CA, 94025, USA
| | - H T Gazda
- Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.,Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - S Lin
- Department of Molecular, Cell and Development Biology, University of California, Los Angeles, CA, 90095, USA
| | - M Serrano
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, 08028, Spain.,Barcelona Institute of Science and Technology (BIST), Barcelona, 08028, Spain.,Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, 08028, Spain
| | - J Flygare
- Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, 22184, Sweden
| | - K M Sakamoto
- Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA.
| |
Collapse
|
20
|
Nagata Y, Sawada R, Sasaki S, Sugano H, Nishimura T, Noguchi M, Yatabe S, Takeda Y, Ito D, Ohkuma M, Nagasaki E, Kosuge M, Amano K, Eto K, Saruta M. P-207 Impact of renal function on CAPOX / FOLFOX adjuvant chemotherapy in colon cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Arima K, Tamai M, Nonaka F, Iwamoto N, Mizukami S, Nishimura T, Abe Y, Origuchi T, Aoyagi K. SAT0458 THE POLYMORPHISM ON FAT MASS AND OBESITY ASSOCIATED GENE (FTO) WAS ASSOCIATED WITH LOW BONE MASS IN JAPANESE COMMUNITY DWELLING POPULATION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:A polymorphism onFTO(OMIM 610966) was reported as a causal variant for obesity, plays a critical rule not only in amount of adipose tissue but also in function of mitochondrial thermogenesis1.Objectives:To examine the association of the genotype on a single nucleotide polymorphism onFTOwith bone health.Methods:FTO rs1421085 polymorphism was genotyped in 1,601 community-dwelling Japanese participants. This cross-sectional study was nested in Nagasaki Islands Study, which is a prospective cohort in Goto City, in islands of Japan. Participants were recruited at medical check-ups for community dwelling population.Bone mass of the calcaneus was evaluated with stiffness index calculated using a quantitative ultrasound measurement. Low bone mass was defined as a stiffness index less than 80 % of the young adult mean.Sera and peripheral blood mononuclear cells were obtained. The SNP of rs1421085 was genotyped using hydrolysis probe. The chi-squared test was used to determine whether the variants were in equilibrium in that population. Trend for the median of BMI among genotypes was assessed using the Jonckheere-Terpstra test. Potential associations between FTO polymorphism and overweight and between the polymorphism and low bone mass were evaluated using logistic regression. All analyses were carried out using SPSS 23.Results:Genotype and allele frequencies for the polymorphism were in Hardy-Weinberg equilibrium (minor allele frequency 0.16, p = 0.40) in 1,601 community-dwelling persons (mean age was 68.5 years in men and 68.1 years in women).There were significant associations between the minor allele and higher median of BMI on dose dependent manner in men (p = 0.04 for trend in men and p = 0.10 for trend in women, respectively), and between the minor allele and overweight (>25 in BMI, OR 1.52, 95%CI 1.07 2.14, p=0.02 in men, OR 1.48, 95%CI 1.16 1.95, p=0.01 in women).Logistic regression analysis showed a significant protective association in men with carriers of minor allele against low bone mass after an adjustment for age and BMI (OR 0.63, 95%CI 0.44 0.90, p=0.01 in men, not significant in women).Conclusion:Our study indicated significant associations of the polymorphism onFTOwith BMI and bone mass among community dwelling men. The polymorphism may play a rule in a part of bone health with higher BMI and other beneficial functions.References:[1]N Engl J Med. 2015; 373: 895-907Disclosure of Interests:None declared
Collapse
|
22
|
Nishikawa T, Matsuzawa T, Ohta K, Uchida N, Nishimura T, Ide S. The slow earthquake spectrum in the Japan Trench illuminated by the S-net seafloor observatories. Science 2020; 365:808-813. [PMID: 31439795 DOI: 10.1126/science.aax5618] [Citation(s) in RCA: 92] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Accepted: 07/11/2019] [Indexed: 11/02/2022]
Abstract
Investigating slow earthquake activity in subduction zones provides insight into the slip behavior of megathrusts, which can provide important clues about the rupture extent of future great earthquakes. Using the S-net ocean-bottom seismograph network along the Japan Trench, we mapped a detailed distribution of tectonic tremors, which coincided with very-low-frequency earthquakes and a slow slip event. Compiling these and other related observations, including repeating earthquakes and earthquake swarms, we found that the slow earthquake distribution is complementary to the Tohoku-Oki earthquake rupture. We used our observations to divide the megathrust in the Japan Trench into three along-strike segments characterized by different slip behaviors. We found that the rupture of the Tohoku-Oki earthquake, which nucleated in the central segment, was terminated by the two adjacent segments.
Collapse
Affiliation(s)
- T Nishikawa
- Disaster Prevention Research Institute, Kyoto University, Uji, Japan.
| | - T Matsuzawa
- National Research Institute for Earth Science and Disaster Resilience, Tsukuba, Japan
| | - K Ohta
- Disaster Prevention Research Institute, Kyoto University, Uji, Japan
| | - N Uchida
- Graduate School of Science and International Research Institute of Disaster Science, Tohoku University, Sendai, Japan
| | - T Nishimura
- Disaster Prevention Research Institute, Kyoto University, Uji, Japan
| | - S Ide
- Department of Earth and Planetary Science, University of Tokyo, Tokyo, Japan
| |
Collapse
|
23
|
Shimojo Y, Nishimura T, Hazama H, Ito N, Awazu K. Picosecond Laser-Induced Photothermal Skin Damage Evaluation by Computational Clinical Trial. Laser Ther 2020; 29:61-72. [PMID: 32903975 DOI: 10.5978/islsm.20-or-08] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 04/23/2020] [Indexed: 01/07/2023]
Abstract
Background and Objectives Computational clinical trial (CCT) in the field of laser medicine promotes clinical application of novel laser devices, because this trial carried out based on numerical modeling of laser-tissue interactions and simulation of a series of treatment process. To confirm the feasibility of the computational clinical trial of skin treatment with a novel picosecond laser, this paper presents an evaluation method of the safety. Study Design/Materials and Methods In this method, the light propagation and thermal diffusion process after ultrashort light pulse irradiation to a numerical skin model is calculated and the safety based on the photothermal damage is evaluated by computational modeling and simulation. As an example, the safety of a novel picosecond laser device was examined by comparing with several laser devices approved for clinical use. Results The ratio of the maximum thermal damage induced by picosecond laser irradiation was 1.2 × 10-2 % at the epidermis, while that caused by approved laser irradiation was 99 % at the capillary vessels. The numerical simulation demonstrated that less thermal damage was observed compared with the approved devices. The results show the safety simulated by photothermal damage calculation was consistent with the reported clinical trials. Conclusions This computational clinical trial shows the feasibility of applying computational clinical trials for the safety evaluation of novel medical laser devices. In contrast to preclinical and clinical tests, the proposed computational method offers regulatory science for appropriately and quickly predicting and evaluating the safety of a novel laser device.
Collapse
Affiliation(s)
- Y Shimojo
- Graduate School of Engineering, Osaka University, Suita, Japan
| | - T Nishimura
- Graduate School of Engineering, Osaka University, Suita, Japan
| | - H Hazama
- Graduate School of Engineering, Osaka University, Suita, Japan
| | - N Ito
- Global Center for Medical Engineering and Informatics, Osaka University, Suita, Japan
| | - K Awazu
- Graduate School of Engineering, Osaka University, Suita, Japan.,Global Center for Medical Engineering and Informatics, Osaka University, Suita, Japan.,Graduate School of Frontier Biosciences, Osaka University, Suita, Japan
| |
Collapse
|
24
|
Kodaira T, Kagami Y, Shibata T, Shikama N, Nishimura Y, Ishikura S, Nakamura K, Saito Y, Matsumoto Y, Teshima T, Ito Y, Akimoto T, Nakata K, Toshiyasu T, Nakagawa K, Nagata Y, Nishimura T, Uno T, Kataoka M, Yorozu A, Hiraoka M. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701). Ann Oncol 2019; 29:992-997. [PMID: 29401241 DOI: 10.1093/annonc/mdy036] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background We assessed the non-inferiority of accelerated fractionation (AF) (2.4 Gy/fraction) compared with standard fractionation (SF) (2 Gy/fraction) regarding progression-free survival (PFS) in patients with T1-2N0M0 glottic cancer (GC). Patients and methods In this multi-institutional, randomized, phase III trial, patients were enrolled from 32 Japanese institutions. Key inclusion criteria were GC T1-2N0M0, age 20-80, Eastern Cooperative Oncology Group performance status of 0-1, and adequate organ function. Patients were randomly assigned to receive either SF of 66-70 Gy (33-35 fractions), or AF of 60-64.8 Gy (25-27 fractions). The primary end point was the proportion of 3-year PFS. The planned sample size was 360 with a non-inferiority margin of 5%. Results Between 2007 and 2013, 370 patients were randomized (184/186 to SF/AF). Three-year PFS was 79.9% (95% confidence interval [CI] 73.4-85.4) for SF and 81.7% (95% CI 75.4-87.0) for AF (difference 1.8%, 91% CI-5.1% to 8.8%; one-sided P = 0.047 > 0.045). The cumulative incidences of local failure at 3 years for SF/AF were 15.9%/10.3%. No significant difference was observed in 3-year overall survival (OS) between SF and AF. Grade 3 or 4 acute and late toxicities developed in 22 (12.4%)/21 (11.5%) and 2 (1.1%)/1 (0.5%) in the SF/AF arms. Conclusion Although the non-inferiority of AF was not confirmed statistically, the similar efficacy and toxicity of AF compared with SF, as well as the practical convenience of its fewer treatment sessions, suggest the potential of AF as a treatment option for early GC. Clinical trials registration UMIN Clinical Trial Registry, number UMIN000000819.
Collapse
Affiliation(s)
- T Kodaira
- Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
| | - Y Kagami
- Department of Radiation Oncology, Showa University, Tokyo, Japan
| | - T Shibata
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
| | - N Shikama
- Department of Radiation Oncology, Juntendo University, Tokyo, Japan
| | - Y Nishimura
- Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - S Ishikura
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - K Nakamura
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
| | - Y Saito
- Department of Radiation Oncology, Saitama Cancer Center, Saitama, Japan
| | - Y Matsumoto
- Department of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan
| | - T Teshima
- Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan
| | - Y Ito
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - T Akimoto
- Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - K Nakata
- Department of Radiology, Sapporo Medical University, Sapporo, Japan
| | - T Toshiyasu
- Department of Radiation Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - K Nakagawa
- Department of Radiology, Tokyo University, Tokyo, Japan
| | - Y Nagata
- Department of Radiation Oncology, Hiroshima University, Hiroshima, Japan
| | - T Nishimura
- Department of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - T Uno
- Department of Radiology, Chiba University Hospital, Chiba, Japan
| | - M Kataoka
- Department of Radiation Oncology, Shikoku Cancer Center, Matsuyama, Japan
| | - A Yorozu
- Department of Radiology, Tokyo Medical Center, Tokyo, Japan
| | - M Hiraoka
- Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Hospital, Kyoto, Japan
| | | |
Collapse
|
25
|
Nagata Y, Kinoshita C, Ishimoto U, Kano T, Ishikawa M, Mikuni H, Nakatsuka K, Harada K, Nishimura T, Noguchi M, Sawada R, Amano K, Saruta M. Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Ishida T, Tomii K, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim Y, Yoshimura K, Hirai T. Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Ishii J, Takahashi H, Nishimura T, Kawai H, Muramatsu T, Harada M, Yamada A, Naruse H, Hayashi M, Motoyama S, Sarai M, Watanabe E, Izawa H, Ozaki Y. P4620Circulating concentration of presepsin improves early prediction of short-term mortality in patients treated at medical cardiac intensive care units. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Presepsin, a subtype of soluble CD14, is an inflammatory marker, which largely reflects monocytic activation. Presepsin appears to be an accurate diagnostic marker of sepsis, but its clinical significance remains unclear in cardiovascular disease.
Purpose
This prospective study aimed to investigate the predictive value of plasma presepsin levels on admission to medical (non-surgical) cardiac intensive care units (MCICUs) for short-term mortality.
Methods
We examined 1560 patients hospitalized in MCICUs and measured the baseline plasma presepsin levels at admission.
Results
Acute coronary syndrome was present in 46% of the patients, and acute decompensated heart failure in 36%. Before MCICUs admission, emergent coronary angiography or percutaneous coronary intervention was performed in 36%, mechanical ventilation was required for respiratory insufficiency in 2.1%, and intraaortic balloon pumps were needed for hemodynamic instability in 8.9%. During 6 months after admission, there were 113 (7.2%) deaths. Patients who died were older (median: 77 vs. 71 years, P<0.0001); had higher levels of presepsin (263 vs. 119 pg/mL, P<0.0001), B-type natriuretic peptide (BNP: 696 vs. 186 pg/mL, P<0.0001), high-sensitivity troponin T (hsTnT: 81 vs. 47 pg/mL, P=0.004), and high-sensitivity C-reactive protein (13.8 vs. 2.2 mg/L, P<0.0001); and had lower levels of estimated glomerular filtration rate (50 vs. 65 mL/min/1.73m2, P<0.0001) and left ventricular ejection fraction (43% vs. 51%, P<0.0001) than those of the survivors. In the multivariate Cox regression analysis, higher levels of presepsin (P=0.0002), BNP (P=0.04), and hsTnT (P=0.009) were all independent predictors of 6-month deaths. Quartiles of presepsin levels were associated with higher mortality rates within 6 months after admission (Table). Adding presepsin levels to a baseline model that included established risk factors, BNP, and hsTnT further enhanced reclassification (P=0.004) and discrimination (P=0.003) beyond that of the baseline model.
Mortality rates according to presepsin Presepsin quartile 1st 2nd 3rd 4th P value ≤80 pg/mL 81–124 pg/mL 125–232 pg/mL >232 pg/mL 1-month mortality 0.8% 2.0% 3.3% 8.0% <0.0001 6-month mortality 0.8% 3.8% 8.2% 16.3% <0.0001
Conclusions
Presepsin levels at admission could improve the prediction of short-term mortality in patients hospitalized at MCICUs.
Collapse
Affiliation(s)
- J Ishii
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Takahashi
- Division of Statistics, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Nishimura
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Kawai
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Muramatsu
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Harada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - A Yamada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Naruse
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Hayashi
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - S Motoyama
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Sarai
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - E Watanabe
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Izawa
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - Y Ozaki
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| |
Collapse
|
28
|
Kawamura H, Shoda Y, Terachi T, Katsumura Y, Uchida S, Mizuno T, Muroya Y, Tsuzuki Y, Umehara R, Hirano H, Nishimura T. PWR secondary water chemistry guidelines in Japan - Purpose and technical background. Progress in Nuclear Energy 2019. [DOI: 10.1016/j.pnucene.2019.01.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Nishimura T, Sakai H, Mori H, Akiba K, Usui H, Ochi M, Kuroki K, Miyake A, Tokunaga M, Uwatoko Y, Katayama K, Murakawa H, Hanasaki N. Large Enhancement of Thermoelectric Efficiency Due to a Pressure-Induced Lifshitz Transition in SnSe. Phys Rev Lett 2019; 122:226601. [PMID: 31283289 DOI: 10.1103/physrevlett.122.226601] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Revised: 04/18/2019] [Indexed: 06/09/2023]
Abstract
The Lifshitz transition, a change in Fermi surface topology, is likely to greatly influence exotic correlated phenomena in solids, such as high-temperature superconductivity and complex magnetism. However, since the observation of Fermi surfaces is generally difficult in the strongly correlated systems, a direct link between the Lifshitz transition and quantum phenomena has been elusive so far. Here, we report a marked impact of the pressure-induced Lifshitz transition on thermoelectric performance for SnSe, a promising thermoelectric material without a strong electron correlation. By applying pressure up to 1.6 GPa, we have observed a large enhancement of the thermoelectric power factor by more than 100% over a wide temperature range (10-300 K). Furthermore, the high carrier mobility enables the detection of quantum oscillations of resistivity, revealing the emergence of new Fermi pockets at ∼0.86 GPa. The observed thermoelectric properties linked to the multivalley band structure are quantitatively reproduced by first-principles calculations, providing novel insight into designing the SnSe-related materials for potential valleytronic as well as thermoelectric applications.
Collapse
Affiliation(s)
- T Nishimura
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Sakai
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
- PRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan
| | - H Mori
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - K Akiba
- The Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - H Usui
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Ochi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - K Kuroki
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - A Miyake
- The Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - M Tokunaga
- The Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - Y Uwatoko
- The Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - K Katayama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Murakawa
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - N Hanasaki
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| |
Collapse
|
30
|
Honma H, Tsushima D, Kawakami H, Fujihara N, Tsusaka T, Kawashimo M, Nishimura T, Fuji S. Complete nucleotide sequence of a new potexvirus, 'Cnidium virus X', isolated from Cnidium officinale in Japan. Arch Virol 2019; 164:1931-1935. [PMID: 31011816 DOI: 10.1007/s00705-019-04261-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 03/27/2019] [Indexed: 10/27/2022]
Abstract
A flexuous virus was detected in a Cnidium officinale plant in Japan showing mosaic symptoms. The virus was assigned to the genus Potexvirus based on analysis of its complete nucleotide sequence. The genomic RNA of the virus was 5,964 nucleotides in length, excluding the 3'-terminal poly(A) tail. It contained five open reading frames (ORFs), consistent with other members of Potexvirus. The ORF sequences differ from those of previously reported potexviruses. Phylogenetic analysis indicated that the polymerase of the virus is closely related to that of strawberry mild yellow edge virus; and the CP, to those of both yam virus X and vanilla virus X. We propose that this virus be designated as "cnidium virus X" (CnVX).
Collapse
Affiliation(s)
- H Honma
- Faculty of Bioresource Sciences, Akita Prefectural University, Akita, Japan
| | - D Tsushima
- Faculty of Bioresource Sciences, Akita Prefectural University, Akita, Japan.
| | - H Kawakami
- Faculty of Bioresource Sciences, Akita Prefectural University, Akita, Japan
| | - N Fujihara
- Botanical Raw Materials Research Laboratories, Tsumura & Co., Ibaraki, Japan
| | - T Tsusaka
- Botanical Raw Materials Research Laboratories, Tsumura & Co., Ibaraki, Japan
| | - M Kawashimo
- Botanical Raw Materials Research Laboratories, Tsumura & Co., Ibaraki, Japan
| | - T Nishimura
- Botanical Raw Materials Research Laboratories, Tsumura & Co., Ibaraki, Japan
| | - S Fuji
- Faculty of Bioresource Sciences, Akita Prefectural University, Akita, Japan
| |
Collapse
|
31
|
Yasui K, Katagiri H, Onoe T, Ogawa H, Harada H, Asakura H, Maki S, Nakura A, Ito Y, Hirata M, Murayama S, Honda Y, Miyagi M, Wasa J, Murata H, Takahashi M, Nishimura T. PO-0880 Validation of a predictive model for survival in patients receiving radiotherapy for bone metastases. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31300-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Sawa Y, Matsumiya G, Matsuda K, Tatsumi E, Abe T, Fukunaga K, Ichiba S, Taguchi T, Kokubo K, Masuzawa T, Myoui A, Nishimura M, Nishimura T, Nishinaka T, Okamoto E, Tokunaga S, Tomo T, Tsukiya T, Yagi Y, Yamaoka T. Journal of Artificial Organs 2018: the year in review : Journal of Artificial Organs Editorial Committee. J Artif Organs 2019; 22:1-5. [PMID: 30796540 DOI: 10.1007/s10047-019-01094-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Y Sawa
- Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
| | - G Matsumiya
- Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan
| | - K Matsuda
- Emergency and Critical Care Medicine, University of Yamanashi Hospital, Yamanashi, Japan
| | - E Tatsumi
- Department of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - T Abe
- Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan
| | - K Fukunaga
- Faculty of Health Sciences, Kyorin University, Tokyo, Japan
| | - S Ichiba
- Department of Surgical Intensive Care Medicine, Nippon Medical School Hospital, Tokyo, Japan
| | - T Taguchi
- Biomaterial Unit, National Institute of Material Science, Ibaraki, Japan
| | - K Kokubo
- Department of Medical Engineering and Technology, Kitasato University School of Allied Health Science, Kanagawa, Japan
| | - T Masuzawa
- Department of Mechanical Engineering, Ibaraki University, Ibaraki, Japan
| | - A Myoui
- Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan
| | - M Nishimura
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Tottori, Japan
| | - T Nishimura
- Department of Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan
| | - T Nishinaka
- Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - E Okamoto
- Department of Human Science and Informatics, School of Bioscience and Engineering, Tokai University, Sapporo, Japan
| | - S Tokunaga
- The Department of Cardiovascular Surgery, JCHO Kyushu Hospital, Fukuoka, Japan
| | - T Tomo
- Second Department of Internal Medicine, Faculty of Medicine, Oita University, Oita, Japan
| | - T Tsukiya
- Department of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Y Yagi
- Department of Clinical Engineering, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Yamaoka
- Department of Biomedical Engineering, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| |
Collapse
|
33
|
Nishimura T, Yoshida K, Kawata Y, Takeuchi Y, Kakiuchi N, Shiozawa Y, Aoki K, Hirata M, Kataoka TR, Sakurai T, Baba S, Shiraishi Y, Chiba K, Takeuchi K, Haga H, Miyano S, Toi M, Ogawa S. Abstract P3-06-04: Clonal evolution of non-malignant proliferative lesions into breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Introduction] Non-malignant proliferative lesions in the breast have been implicated in the development of invasive breast cancer. Previous studies showed that adjacent atypical proliferative lesions and breast cancers shared common genetic alterations, suggesting that these evolved from the same ancestral cell. However, the clonal structure of atypical proliferative lesions and their clonal dynamics during progression to cancer are poorly understood. In this study, we compared genetic profiles (with and without pathogenic germline mutations) of normal mammary ducts, non-malignant proliferative lesions, and cancer tissues from the same patients to illustrate the clonal evolution of cancer from a non-malignant epithelial cell.
[Methods] Multiple samples were collected from different proliferative lesions within the cancer-borne breast, including invasive cancers, using micro-dissection from formalin-fixed, paraffin-embedded surgical specimens. Somatic mutations and copy number alterations (CNAs) were then evaluated by whole exome sequencing.
[Results] We analyzed a total of 34 samples from 5 premenopausal females carrying estrogen receptor-positive cancers, where the samples were obtained from normal ducts (N = 6), non-atypical (N = 1) and atypical (N = 8) proliferative lesions, and non-invasive (N = 16) and invasive (N = 3) cancers. The number of somatic mutations per sample ranged from 1 to 276 and increased with disease progression, regardless of the germline mutation status. Two cases with bilateral cancers had a pathogenic germline mutation of either BRCA2 or TP53, where no somatic mutations or CNAs were shared by individual proliferative lesions, suggesting multifocal independent cancerous evolutions. By contrast, in the remaining three unilateral cases, no pathogenic germline mutations were detected, but all proliferative lesions, which were separated by a distance of 7-25 mm, shared one or more driver alterations, such as an AKT1 mutation (UID: KU01), concurrent 1q gain and 16q loss (der(1;16)) (UID: KU02), and a GATA3 mutation and der(1;16) (UID: KU03), while harboring private mutations and/or CNAs of their own. The phylogenetic analysis based on the number of shared mutations predicted an early origin of these founder mutations, which frequently predated decades before the onset of cancer.
[Conclusions] Our results suggest that early breast cancer development is shaped by the evolution of multiple precancerous clones. These clones are originated from a common ancestor that acquired a founder mutation long before the onset of cancer, followed by branching evolution of multiple clones that acquired additional driver mutations of their own, from which an invasive cancer ultimately develops. In hereditary cases, this process is thought to be substantially promoted multi-focally from within the entire breasts by a germline mutation shared by all mammary cells, frequently resulting in bilateral and/or multifocal breast cancers. Our findings provide unique insight into the early development of breast cancer.
Citation Format: Nishimura T, Yoshida K, Kawata Y, Takeuchi Y, Kakiuchi N, Shiozawa Y, Aoki K, Hirata M, Kataoka TR, Sakurai T, Baba S, Shiraishi Y, Chiba K, Takeuchi K, Haga H, Miyano S, Toi M, Ogawa S. Clonal evolution of non-malignant proliferative lesions into breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-04.
Collapse
Affiliation(s)
- T Nishimura
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Yoshida
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Kawata
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Takeuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - N Kakiuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Shiozawa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Aoki
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - M Hirata
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - TR Kataoka
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - T Sakurai
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Baba
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Shiraishi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Chiba
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Takeuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - H Haga
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Miyano
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - M Toi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Ogawa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
34
|
Obara S, Nakayama H, Kato T, Yamada T, Nakamura Y, Nishimura T, Kito Y, Okamura R. [Gastrointestinal Stromal Tumor of the Small Intestine with Dissemination Successfully Treated with Surgical Resection and Adjuvant Chemotherapy with Sunitinib-A Case Report]. Gan To Kagaku Ryoho 2018; 45:2438-2440. [PMID: 30692490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
We report the case of a 73-year-old woman with repeated recurrent small intestinal gastrointestinal stromal tumor(GIST) who was referred to our hospital for best supportive care. She underwent surgical resection 4 times and developed recurrent tumors that were resistant to imatinib. She complained of right lower abdominal pain caused by the recurrent tumor. We performed surgical resection of the tumor and the disseminated tumors synchronously. Histopathological findings of the resected specimen revealed a high-risk GIST. After the operation, she was administered sunitinib(50mg/day)as adjuvant therapy according to a 4-week-on/2-week-off schedule. Due to the resulting adverse effects, the schedule was changed to 1-week-on/1-week-off therapy. She showed no sign of recurrence 38months after the last surgery. Thus, surgical resection and adjuvant molecular targeted therapy may be an effective treatment strategy for recurrent GIST.
Collapse
|
35
|
Kawaguchi Y, Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, Saito Y, Nagata Y, Matsumo Y, Akimoto T, Nishimura T, Uno T, Tsujino K, Kataoka M, Kodaira T, Shiraishi K, Inoue K, Isohashi F, Hiraoka M. A Multicenter Single-Arm Confirmatory Trial on Hypofractionated Whole-breast Irradiation after Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Onoe T, Murayama S, Harada H, Ito Y, Yasui K, Nakura A, Maki S, Ogawa H, Asakura H, Nishimura T, Katagiri H, Takahashi M, Ishida Y. Efficacy of Proton Beam Radiation Therapy and Chemotherapy in Patients with Ewing Sarcoma Family of Tumors of the Trunk. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Suzuki E, Kotake T, Nishimura T, Yamaguchi A, Pu F, Toi M. Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Honda T, Kouzuki T, Tsunezuka Y, Seki N, Shibayama T, Okimoto T, Taniguchi H, Takeda Y, Hata N, Sugimoto K, Takahashi N, Sakai K, Nishimura T, Ikeda S, Watanabe S, Mori K, Shinkai T. Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (≥75 years old) patients (pts) with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC): TORG1323. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Isoda K, Daibo T, Yushina K, Yoshioka Y, Tsutsumi Y, Akimoto Y, Kawakami H, Taira Y, Taira I, Yanoshita R, Nishimura T, Ishida I. Hepatotoxicity, nephrotoxicity, and drug/chemical interaction toxicity of platinum nanoparticles in mice. Pharmazie 2018; 72:10-16. [PMID: 29441891 DOI: 10.1691/ph.2017.6758] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Nanomaterials are frequently used in microelectronics, cosmetics, and sunscreens. Platinum reagents are commonly used in disease diagnosis, cosmetics, and the food industry. Although research into the development of nanomaterialbased drug delivery systems has yielded promising results, the toxicity of these materials is not fully understood. We investigated the toxicity and drug interactions of 1- and 8-nm diameter platinum nanoparticles (nPt1 and nPt8, respectively) in mice. Acute hepato-renal toxicity of intravenously administered platinum nanoparticles was evaluated biochemically and histologically. Dose-dependent increases in serum markers of hepato-renal function (serum aminotransferases and blood urea nitrogen) were observed following administration of nPt1, whereas nPt8 had no effect, even at 20 mg/kg. Moreover, nPt1 induced interleukin (IL)-6 and IL-1β production 3 and 6 hours after administration. The effect of nPts on drug-induced toxicity was evaluated in mice injected intraperitoneally with carbon tetrachloride or cisplatin, with or without intravenous administration of platinum nanoparticles. All treatments in the absence of nanoparticles were non-lethal and resulted in moderate toxicity. However, exacerbated toxicity was observed in mice injected with carbon tetrachloride or cisplatin together with nPt1, but not in mice co-injected with nPt8. We found that nPt1 cause hepato-renal damage, and the effect is enhanced by chemical inducers of hepatotoxicity and nephrotoxicity. This is the first report demonstrating that nPt1 not only are hepatotoxic and nephrotoxic but also exacerbate drug toxicity. These findings will be useful for future nanotechnology and nanoscience research.
Collapse
|
40
|
Segami N, Nishimura T, Miyaki K, Adachi H. Tethering technique using bone screws and wire for chronic mandibular dislocation: a preliminary study of refractory cases. Int J Oral Maxillofac Surg 2018; 47:1065-1069. [DOI: 10.1016/j.ijom.2018.03.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 02/20/2018] [Accepted: 03/26/2018] [Indexed: 11/26/2022]
|
41
|
Higashi K, Nishimura T, Baba Y, Ishikawa Y, Hiramine K, Tanaka H, Nuruki N, Sonoda M, Tanaka Y. P3565Clopidorel-based antiplatelet therapy is not enough for stent patency in patients undergoing femoropopliteal arterial endovascular interventions. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- K Higashi
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - T Nishimura
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - Y Baba
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - Y Ishikawa
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - K Hiramine
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - H Tanaka
- National Hospital Organization Kagoshima Medical Center, Emergency Department, Kagoshima, Japan
| | - N Nuruki
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - M Sonoda
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| | - Y Tanaka
- National Hospital Organization Kagoshima Medical Center, Second Department of Cardiology, Kagoshima, Japan
| |
Collapse
|
42
|
Yamauchi Y, Okishige K, Shigeta T, Nishimura T, Nakamura R, Aoyagi H, Hirao K. P5753How to create linear conduction block at left atrial roof by cyroballoon catheter. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y Yamauchi
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - K Okishige
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - T Shigeta
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - T Nishimura
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - R Nakamura
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - H Aoyagi
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - K Hirao
- Tokyo Medical and Dental University, Cardiology, Tokyo, Japan
| |
Collapse
|
43
|
Yamauchi Y, Yamauchi Y, Okishige K, Shigeta T, Nishimura T, Aoyagi H, Nakamura R, Hiao K. P1915An underrecognized complication of coronary artery spasm during cryoballoon-guided atrial fibrillation ablation under deep sedation with dexmedetomidine. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1915] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Yamauchi
- Musashino Red Cross Hospital, cardiology, Musashino, Japan
| | - Y Yamauchi
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - K Okishige
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - T Shigeta
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - T Nishimura
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - H Aoyagi
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - R Nakamura
- Yokohama Minato Red Cross Hospital, Cardiology, Yokohama, Japan
| | - K Hiao
- Tokyo Medical and Dental University, Cardiology, Tokyo, Japan
| |
Collapse
|
44
|
Shimada H, Mori T, Takada A, Takada Y, Noda Y, Takai I, Kohda H, Nishimura T. Use of Chromogenic Substrate S-2251 for Determination of Plasminogen Activator in Rat Ovaries. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1653398] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA simple, specific and reproducible method for determination of plasminogen activator activity in rat ovaries has been developed by using the chromogenic substrate S-2251. The two steps of enzymatic reactions, i. e. activation of plasminogen and subsequent hydrolysis of the substrate was performed in one step incubation. A linear relationship was observed between the amount of chromogen produced and activator activity in the range of the optical density from 0.05 to 1.20 for 30 min’s incubation. Endogenous activity of non-specific proteases, plasmin or plasmin inhibitors which might be contained in rat ovaries turned out not to interfere with the specificity of a standardized assay procedure. Reproducibility was firmly established with coefficient of variation not exceeding 10%. Using this method, a marked increase followed by a drastic decrease in the activator activity was shown with rat ovaries around the time of ovulation after the injection of human chorionic gonadotropin.
Collapse
Affiliation(s)
- H Shimada
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| | - T Mori
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| | - A Takada
- The Department of Physiology, School of Medicine, Hamamatsu University, Shizuoka, Japan
| | - Y Takada
- The Department of Physiology, School of Medicine, Hamamatsu University, Shizuoka, Japan
| | - Y Noda
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| | - I Takai
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| | - H Kohda
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| | - T Nishimura
- The Department of Obstetrics and Gynecology, School of Medicine, Kyoto University, Kyoto Japan
| |
Collapse
|
45
|
Park M, Nishimura T, Naudi A, Young T, Pamplona R, Hartley R, Murphy M, Krieg T. MitoGamide ameliorates diabetic cardiomyopathy by scavenging mitochondrial dicarbonyls in type 1 diabetic Akita mice. J Mol Cell Cardiol 2018. [DOI: 10.1016/j.yjmcc.2018.05.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Morser J, Shao Z, Nishimura T, Zhou Q, Zhao L, Higgins J, Leung LLK. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice. J Thromb Haemost 2018; 16:991-1002. [PMID: 29383821 PMCID: PMC8491566 DOI: 10.1111/jth.13964] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Indexed: 12/24/2022]
Abstract
Essentials Two basic carboxypeptidases are present in plasma, B2 (CPB2) and N (CPN). Cpb2-/- and Cpn-/- mice were challenged in a hemolytic uremic syndrome (HUS) model vs. wild type. Cpb2-/- exacerbates HUS while Cpn-/- exacerbates cobra venom factor challenge vs. wild type mice. CPB2 and CPN have overlapping but non-redundant roles. SUMMARY Background There are two basic carboxypeptidases in plasma. Carboxypeptidase B2 (CPB2) is activated from a circulating zymogen, proCPB2, and carboxypeptidase N (CPN) is constitutively active with both inactivating complement C3a and C5a. Aims To test the roles of CPB2 and CPN in complement-driven mouse models of cobra venom factor (CVF) challenge and hemolytic-uremic syndrome (HUS). Methods Cpb2-/- , Cpn-/- and wild-type (WT) mice were compared in an HUS model induced by Shiga toxin and lipopolysaccharide administration and following CVF administration. Results HUS was exacerbated in Cpb2-/- mice more than in Cpn-/- mice, compared with WT mice. Cpb2-/- mice developed the HUS clinical triad of microangiopathic hemolytic anemia, uremia and thrombocytopenia. Treatment with anti-C5 antibody improved survival of both Cpb2-/- and Cpn-/- mice. In contrast, when challenged acutely with CVF, the reverse phenotype was observed. Cpn-/- mice had markedly worse disease than Cpb2-/- mice, whereas the WT mice were resistant. Conclusions CPN and CPB2 play overlapping but non-redundant roles in regulating complement activation in vivo. The constitutively active CPN is key for inactivation of systemic C5a, whereas CPB2 functions as an on-demand supplementary anaphylatoxin inhibitor in inactivating excessive C5a formed locally.
Collapse
Affiliation(s)
- J Morser
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - Z Shao
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - T Nishimura
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - Q Zhou
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - L Zhao
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
| | - J Higgins
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - L L K Leung
- Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
47
|
Akiyama D, Nishimura T, Iizuka K, Mizuno T, Tsukiya T, Takewa Y, Ono M, Tatsumi E. Accurate Quantitative Evaluation of Aortic Insufficiency During LVAD Support by Thermodilution Analysis. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
48
|
Iizuka K, Akiyama D, Takewa Y, Tsukiya T, Mizuno T, Nishimura T, Tatsumi E. Electrocardiogram-synchronized Rotational Speed Modulation System Can Reduce the Recirculation Due to Aortic Insufficiency in LVAD Support. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
49
|
Nishimura T, Tatsumi E, Nishinaka T, Taenaka Y, Nakata M, Takano H. Prolonged Nonpulsatile Left Heart Bypass Diminishes Vascular Contractility. Int J Artif Organs 2018. [DOI: 10.1177/039139889902200707] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We investigated possible functional changes in the vascular system accompanying the morphological change in prolonged nonpulsatile left heart bypass (LHB). Three adult goats underwent pulsatile LHB. Two weeks postoperatively, the pulsatile ventricular assist device was replaced with a centrifugal pump and nonpulsatile LHB was subsequently conducted for 4 weeks. The mean aortic pulse pressure was 39 and 16 mmHg during the pulsatile and nonpulsatile LHB, respectively. Systemic vascular resistance (SVR) and plasma norepinephrine levels were measured at the end of pulsatile LHB (PUL), and at the end of 1st, 2nd, 3rd, and 4th week of nonpulsatile LHB (NP1w, NP2w, NP3w, NP4w, respectively). At each point, 50 μg/kg nitroglycerin and 1μg/kg norepinephrine were injected and the minimal and maximal values of SVR after injection were calculated as parameters reflecting the vascular tonus and contractility. The SVR and plasma nor epinephrine level did not significantly change during the entire course (SVR: 1106, 895, 982, 920, and 938 dyne·sec·cm−5; norepinephrine level: 0.3, 0.2, 0.1, 0.2, and 0.1 ng/ml; at PUL, NP1w, NP2w, NP3w, and NP4w, respectively). The minimal value of SVR after nitroglycerin injection remained unchanged, indicating that vascular tonus was stable during the entire course (618, 687, 623, 560, 653 dyne·sec·cm−5, respectively). In contrast, the maximal value of SVR after norepinephrine injection at NP3w and NP4w (1695 and 1759 yne·sec·cm−5) became significantly reduced compared to that at PUL (2346 dyne·sec·cm−5). These results indicated that prolonged nonpulsatile left heart bypass did not affect the vascular tonus, but significantly diminished the vascular contractility.
Collapse
Affiliation(s)
- T. Nishimura
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| | - E. Tatsumi
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| | - T. Nishinaka
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| | - Y Taenaka
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| | - M. Nakata
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| | - H. Takano
- Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka - Japan
| |
Collapse
|
50
|
Tamaoki M, Komatsuzaki R, Komatsu M, Minashi K, Aoyagi K, Nishimura T, Chiwaki F, Hiroki T, Daiko H, Morishita K, Sakai Y, Seno H, Chiba T, Muto M, Yoshida T, Sasaki H. Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Sci 2018; 109:1121-1134. [PMID: 29427302 PMCID: PMC5891185 DOI: 10.1111/cas.13531] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 01/25/2018] [Accepted: 02/02/2018] [Indexed: 12/16/2022] Open
Abstract
Degree of histological differentiation is an important characteristic of cancers and may be associated with malignant potential. However, in squamous cell carcinomas, a key transcriptional factor regulating tumor differentiation is largely unknown. Chemoradiotherapy (CRT) is a standard treatment for locally advanced esophageal squamous cell carcinoma; however, the survival rate is still below 40%. From microarray data, single‐minded 2 (SIM2) was overexpressed in the epithelial subtype. Here, we investigated the correlation between SIM2 expression and its clinical implication, and in vitro and in vivo functions of SIM2 in tumor differentiation and in CRT sensitivity. Although SIM2 was suppressed in cancerous tissues, SIM2‐high ESCC showed a favorable prognosis in CRT. Transient SIM2 expression followed by 3D culture induced expression of differentiation markers and suppressed epithelial‐mesenchymal transition‐ and basal‐cell markers. Levels of PDPN‐high tumor basal cells and of expression of genes for DNA repair and antioxidant enzymes were reduced in stable transfectants, and they showed high CDDP and H2O2 sensitivities, and their xenografts showed a well‐differentiated histology. Reduction of tumor basal cells was restored by knockdown of aryl hydrocarbon receptor nuclear translocator (ARNT) that interacted with SIM2. Together, SIM2 increases CRT sensitivity through tumor differentiation by cooperation with ARNT.
Collapse
Affiliation(s)
- Masashi Tamaoki
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan.,Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Rie Komatsuzaki
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| | - Masayuki Komatsu
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| | - Keiko Minashi
- Department of Clinical Trial Promotion, Chiba Cancer Center, Chiba, Japan
| | - Kazuhiko Aoyagi
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| | - Takao Nishimura
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan.,Department of Gastrointestinal Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Fumiko Chiwaki
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| | - Tomoko Hiroki
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| | - Hiroyuki Daiko
- Esophageal Surgery Division, National Cancer Center, Tokyo, Japan
| | | | - Yoshiharu Sakai
- Department of Gastrointestinal Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hiroshi Seno
- Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Tsutomu Chiba
- Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Manabu Muto
- Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Teruhiko Yoshida
- Fundamental Innovative Oncology Core Center, National Cancer Center, Tokyo, Japan
| | - Hiroki Sasaki
- Department of Translational Oncology, National Cancer Center, Tokyo, Japan
| |
Collapse
|